Skip to content

The inhibitory effects on UV-induced skin deterioration by long-term ingestion of test food in human: a double-blind, randomized placebo-controlled, parallel comparison study

The inhibitory effects on UV-induced skin deterioration by long-term ingestion of test food in human: a double-blind, randomized placebo-controlled, parallel comparison study - The inhibitory effects on UV-induced skin deterioration by long-term ingestion of test food in human

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028925
Enrollment
20
Registered
2019-03-30
Start date
2017-09-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Sponsors

DRC Corporation, Ltd. Product Testing Department No.9 Tabuchi Bldg. 3F, 2-10-31, Higashi-Temma, Kita-ku, Osaka Tel: 81-(0)6-6882-1130
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects aged from 30 to 59 years old at the time informed consent is provided. 2) Subjects whose skin phototype is type II or type III. 3) Subjects who accept the analysis for UV-induced erythema in their back skin. 4) Subjects whose basement MED is judged as second, third or fourth points in six-grade UV-irradiated area. 5) Subjects who can visit to the administrative facility on every inspection day. 6) Subjects who provide the written informed consent for the involvement of this trial by themselves.

Exclusion criteria

Exclusion criteria: 1)Subjects with photosensitivity disorder 2)Subjects who take medicine that affect light sensitivity of skin 3)Subjects who regularly go to a dermatology office 4)Subjects who continuously take a functional food or a quasi-medicine which has same or similar effect with ingredient of test food 5)Subjects who continuously take medicine, quasi-medicine, functional food or supplement which advocate or emphasize efficacy for which is evaluated in the trial, or which is related to joint pain 6)Subjects who have skin disease or abnormality in skin condition such as atopic dermatitis 7)Subjects who show apparent change of skin condition that is not related to test food at the end of trial compared with the initiation 8)Subjects who take anti-inflammatory medicine at least once a month 9)Subjects who work on night shift or day and night shift 10)Subjects who receive medical or prophylactic treatment, or who require medical treatment 11)Subjects who have a past history for severe disease or abnormality in glucose or lipid metabolism, liver or kidney function, cardiovascular, respiratory, endocrine or nerve system, or for psychiatric disorder 12)Subjects who have a past history of alcoholism or drug addiction 13)Subjects who have risk for food allergy 14)Subjects who frequently intake food which is rich in same ingredient of test food, or who intake these kind of food during 3 days before and after trial initiation and last 3 days from the end of trial 15)Subjects who frequently intake food which might affect skin color 16)Subjects who show abnormality in blood test, or who are positive for HBs antigen or HCV antibody 17)Subjects who are pregnant or during lactation when the informed consent is provided, or who hope to become pregnant 18)Subjects who were involved in another trial within 4 weeks prior to the trial, or who will participate in another trial 19)Subjects who are judged to be inappropriate for the trial by the responsible doctor

Design outcomes

Primary

MeasureTime frame
MED

Secondary

MeasureTime frame
Skin condition Safety evaluation

Countries

Japan

Contacts

Public ContactYuri Okano

CIEL Corporation CIEL Corporation

yuri.okano@ciel-tokyo.com03-6659-2767

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026